AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the promotion of Mark P. Colonnese to Executive Vice President, Commercial Operations; Rob Scott, M.D. to Executive Vice President, Research and Development; and W. Charles Montgomery, Ph.D. to Senior Vice President, Business Development and Alliance Management. Mr. Colonnese and Drs. Scott and Montgomery will continue to serve on the Company’s executive committee and report to Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics.
